Safety of Russian-backbone seasonal trivalent, live-attenuated influenza vaccine in a phase II randomized placebo-controlled clinical trial among children in urban Bangladesh

Vaccine

Volumn 33, Issue 29, 2015, Pages 3415-3421

  Ortiz, Justin R ^a,b   Goswami, Doli ^c   Lewis, Kristen D C ^a   Sharmeen, Amina Tahia ^c   Ahmed, Moshtaq ^c   Rahman, Mustafizur ^c   Rahman, Mohammed Z ^c   Feser, Jodi ^a   Neuzil, Kathleen M ^a,b   Brooks, W Abdullah ^c,d  

^a PATH   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c INTERNATIONAL CENTRE FOR DIARRHOEAL DISEASE RESEARCH   (Bangladesh)

^d JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Clinical trial; Live attenuated influenza vaccine

Indexed keywords

ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; ANTIPYRETIC AGENT; ANTITUSSIVE AGENT; BRONCHODILATING AGENT; INFLUENZA VACCINE; PARACETAMOL; PLACEBO; LIVE VACCINE;

ABDOMINAL PAIN; ACUTE GASTROENTERITIS; ALLERGY; ARTICLE; ASTHMA; BANGLADESH; CHILD; CONTROLLED STUDY; COUGHING; DIARRHEA; DISEASE SURVEILLANCE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG OVERDOSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; FRACTURE; GIARDIASIS; HELMINTHIASIS; HOSPITALIZATION; HUMAN; INFANT; INFECTION; INFLUENZA; INFLUENZA A; INFLUENZA B; INFLUENZA VACCINATION; INFLUENZA VIRUS; INJURY; KNEE INJURY; LABORATORY TEST; LETHARGY; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; NOSE OBSTRUCTION; OTALGIA; PHASE 2 CLINICAL TRIAL; PRESCHOOL CHILD; PRIORITY JOURNAL; PROFESSIONAL PRACTICE; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; RHINORRHEA; RISK FACTOR; SCABIES; SINGLE DRUG DOSE; SKIN ABSCESS; SORE THROAT; TACHYPNEA; THRUSH; URBAN POPULATION; VACCINATION REACTION; VOMITING; WHEEZING; ABNORMAL RESPIRATORY SOUND; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; INFLUENZA, HUMAN; PATHOLOGY;

BANGLADESH; CHILD, PRESCHOOL; DOUBLE-BLIND METHOD; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HOSPITALIZATION; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; PLACEBOS; RESPIRATORY SOUNDS; VACCINES, ATTENUATED;

EID: 84931567584     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.04.048     Document Type: Article

References (23)

1. Lozano R., Naghavi M., Foreman K., Lim S., Shibuya K., Aboyans V., et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012, 380:2095-2128.
2. Nair H., Brooks W.A., Katz M., Roca A., Berkley J.A., Madhi S.A., et al. Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis. Lancet 2011, 378:1917-1930.
3. World Health Organization Global survey on seasonal influenza vaccine policy development and implementation-2006 2008, World Health Organization, Geneva, Switzerland. World Health Organization (Ed.).
4. Osterholm M.T., Kelley N.S., Sommer A., Belongia E.A. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis 2012, 12:36-44.
5. Ashkenazi S., Vertruyen A., Aristegui J., Esposito S., McKeith D.D., Klemola T., et al. Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections. Pediatr Infect Dis J 2006, 25:870-879.
6. Belshe R.B., Edwards K.M., Vesikari T., Black S.V., Walker R.E., Hultquist M., et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 2007, 356:685-696.
7. Fleming D.M., Crovari P., Wahn U., Klemola T., Schlesinger Y., Langussis A., et al. Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma. Pediatr Infect Dis J 2006, 25:860-869.
8. MedImmune Flumist Quadrivalent package insert 2013, MedImmune, Gaithersburg, MD.
9. Rudenko L.G., Lonskaya N.I., Klimov A.I., Vasilieva R.I., Ramirez A. Clinical and epidemiological evaluation of a live, cold-adapted influenza vaccine for 3-14-year-olds. Bull World Health Organ 1996, 74:77-84.
10. Rudenko L., van den Bosch H., Kiseleva I., Mironov A., Naikhin A., Larionova N., et al. Live attenuated pandemic influenza vaccine: clinical studies on A/17/California/2009/38 (H1N1) and licensing of the Russian-developed technology to WHO for pandemic influenza preparedness in developing countries. Vaccine 2011, 29(Suppl. 1):A40-A44.
11. Serum Institute of India Nasovac-S 2014, Serum Institute of India.
12. Lewis K., Rahman M.Z., Levine M., Ortiz J.R., Katz J., Fry A., et al. Immunogenicity and viral shedding of a seasonal trivalent live attenuated influenza virus vaccine among children in Bangladesh. Macrae foundation's XVII international symposium on respiratory viral infections 2015, P-P14. M. Foundation (Ed.).
13. Brooks W.A., Goswami D., Rahman M., Nahar K., Fry A.M., Balish A., et al. Influenza is a major contributor to childhood pneumonia in a tropical developing country. Pediatr Infect Dis J 2010, 29:216-221.
14. Fry A.M., Goswami D., Nahar K., Sharmin A.T., Rahman M., Gubareva L., et al. Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial. Lancet Infect Dis 2014, 14:109-118.
15. Dhere R., Yeolekar L., Kulkarni P., Menon R., Vaidya V., Ganguly M., et al. A pandemic influenza vaccine in India: from strain to sale within 12 months. Vaccine 2011, 29(Suppl. 1):A16-A21.
16. World Health Organization Recommended composition of influenza virus vaccines for use in the 2012-2013 northern hemisphere influenza season 2011, World Health Organization.
17. Friede M., Palkonyay L., Alfonso C., Pervikov Y., Torelli G., Wood D., et al. WHO initiative to increase global and equitable access to influenza vaccine in the event of a pandemic: supporting developing country production capacity through technology transfer. Vaccine 2011, 29(Suppl. 1):A2-A7.
18. Dawood F.S., Fry A.M., Goswami D., Sharmeen A., Nahar K., Abdullah Brooks W. Incidence and characteristics of early childhood wheezing and the contribution of respiratory viruses, Dhaka, Bangladesh, 2004-2010. XVI international symposium on respiratory viral infections 2013.
19. Bergen R., Black S., Shinefield H., Lewis E., Ray P., Hansen J., et al. Safety of cold-adapted live attenuated influenza vaccine in a large cohort of children and adolescents. Pediatr Infect Dis J 2004, 23:138-144.
20. Masoli M., Fabian D., Holt S., Beasley R. The global burden of asthma: executive summary of the GINA dissemination committee report. Allergy 2004, 59:469-478.
21. Clinicaltrials.gov Clinical efficacy of trivalent live-attenuated influenza vaccine (LAIV) among children in senegal. NCT01854632 2013, Clinicaltrials.gov.
22. Clinicaltrials.gov A randomized, controlled trial on the efficacy and safety of live-attenuated influenza vaccine (LAIV) among children in Bangladesh. NCT01797029 2012, Clinicaltrials.gov.
23. Victor J., Diallo A., Niang M., Ortiz J.R., Diop D., Sugimoto J., et al. Effectiveness of seasonal influenza vaccination of children in tropical developing Africa: a cluster-randomized trial. Options for the control of influenza VIII, Cape Town, South Africa 2013, International Society for Influenza and other Respiratory Virus Diseases.